Drugs / Autologous Plasmablasts
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04284254 | Dec 2022 → Jun 2023 | Hurler syndrome | Masonic Cancer Center, University of Minnesota | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous Plasmablasts | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04284254 ↗ |
| Modality | Cell therapy | “Autologous Plasmablasts engineered to express α-L-iduronidase (IDUA) using the Sleeping Beauty transposon system.” NCT04284254 ↗ |